Hematologic Glyco-Signatures: Emerging Blood-Based Sugar Codes Linked to Hyper-Aggressive Breast Cancer

Emmanuel Ifeanyi Obeagu1– 3 1Division of Haematology, Department of Biomedical and Laboratory Science, Africa University Mutare, Mutare, Zimbabwe; 2Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; 3Department of Medical Laboratory Science, Kampala International University, Ishaka, UgandaCorrespondence: Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe, Email [email protected]: Emerging evidence suggests that aberrant glycosylation patterns in cancer are not confined to tumor tissues but are also reflected systemically in circulating blood components. In hyper-aggressive breast cancer phenotypes, including triple-negative and inflammatory subtypes, distinct alterations in glycoproteins, immunoglobulins, and extracellular vesicle-associated glycans have been reported. These hematologic glyco-signatures represent dynamic “sugar codes” shaped by dysregulated glycosyltransferase activity, inflammatory signaling, and tumor–host interactions. This narrative review synthesizes current knowledge on blood-based glycosylation alterations associated with aggressive breast cancer biology, emphasizing their mechanistic relevance to immune modulation, metastatic dissemination, and tumor progression. Particular attention is given to altered sialylation, fucosylation, and glycan branching patterns observed in circulating proteins, as well as their potential role in immune evasion through lectin–glycan interactions. While hematologic glyco-signatures show promise as minimally invasive biomarkers for diagnosis, prognosis, and disease monitoring, current evidence remains largely exploratory and heterogeneous. Significant challenges persist, including analytical variability, lack of standardized platforms, and limited large-scale clinical validation. Moreover, the causal versus correlative role of circulating glyco-alterations in tumor aggressiveness remains under active investigation. In conclusion, hematologic glyco-signatures represent a promising but still evolving frontier in breast cancer biomarker research. Their integration into clinical oncology will require rigorous validation, harmonization of glycomics methodologies, and comparative studies with established liquid biopsy approaches such as circulating tumor DNA and circulating tumor cells.Keywords: hematologic glyco-signatures, breast cancer, glycomics, biomarkers, tumor aggressiveness